ivermectin oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...118119120121122123124125126127128129130»
  • ||||||||||  ivermectin / Generic mfg.
    Journal:  Human myiasis in Ecuador. (Pubmed Central) -  Apr 26, 2020   
    Ivermectin, when it became available, was used to treat furuncular, wound, and cavitary lesions successfully...Human myiasis is a neglected and understudied ectoparasitic infestation, being endemic in both temperate and tropical regions of Ecuador. Improved education and awareness among populations living in, visitors to, and health personnel working in high-risk regions, is required for improved epidemiological surveillance, prevention, and correct diagnosis and treatment.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Review, Journal:  ANTIVIRAL TREATMENT OF COVID-19. (Pubmed Central) -  Apr 26, 2020   
    Despite the urgent need to find an effective antiviral treatment for COVID-19 through randomized controlled studies, certain agents are being used all over the world based on either in-vitro or extrapolated evidence or observational studies. The most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir and remdesivir will be reviewed here .Nitazoxanide and ivermectin were also included in this review as they have recently been reported to have an activity against SARS-CoV-2 in-vitro and are licensed for the treatment of some other human infections.
  • ||||||||||  ivermectin / Generic mfg.
    Journal:  Characterization and optimization of abamectin-a powerful antiparasitic from a local Streptomyces avermitilis isolate. (Pubmed Central) -  Apr 25, 2020   
    Avermectins (AVMs) and their naturally occurring analogues, milbemycins (MILs), meilingmycins (MEIs), ivermectin (IVE), abamectin (ABA), and nemadectin (NEM), represent one of the most developed antiparasitic agents...The process of identification was carried out by using production medium containing 30 g/L corn starch, and 0.725 g/L CaCO, pH 7, 8% inoculum size and incubated at 32.5 °C. The enhancement of the production of abamectin is a big challenge with commercial and industrial importance, as its output is insufficient for human consumption.
  • ||||||||||  ivermectin / Generic mfg., albendazole / Generic mfg.
    Journal:  Gastrointestinal nematode infections do not hinder the development of Simmental X Nellore crossbred calves raised with a nutritionally enhanced diet. (Pubmed Central) -  Apr 23, 2020   
    The calves received dietary supplementation before and after weaning, which enabled them to gain weight in every month of the experiment and reach a body weight of about 250 kg on the last sampling date, before turning one year old. The anthelmintic treatments did not affect body weight gain, leading to the conclusion that, when fed with suitable dietary supplements, Simmental X Nellore crossbred calves are not affected by gastrointestinal nematode parasites acquired by grazing.
  • ||||||||||  ivermectin / Generic mfg.
    Clinical, Review, Journal:  Clinico-epidemiological spectrum of strongyloidiasis in India: Review of 166 cases. (Pubmed Central) -  Apr 23, 2020   
    Better awareness and early clinical suspicion of the disease with stool microscopy and adequate therapy are necessary to improve the outcome. Strongyloidiasis is rather widely prevalent infection with variable symptomatology and calls for a close coordination from family physicians and microbiologists.
  • ||||||||||  ivermectin / Generic mfg.
    Journal:  Evidence of nuclear transport mechanisms in the protozoan parasite Giardia lamblia. (Pubmed Central) -  Apr 22, 2020   
    This suggests that Importin α and Importin β are key transporters during the encystation process and are involved, at least, in the transport of arginine deiminase into the nuclei. Considering the effect produced by Ivermectin during growth and encystation, we postulate that this drug could be used to treat giardiasis.
  • ||||||||||  ivermectin / Generic mfg.
    Journal:  Dung Beetle Body Condition: A Tool for Disturbance Evaluation in Contaminated Pastures. (Pubmed Central) -  Apr 19, 2020   
    Our work suggests that ivermectin may be a useful addition to the treatment armamentarium for ovarian cancer and that targeting Akt/mTOR signaling is a therapeutic strategy to increase chemosensitivity in ovarian cancer. In the present study, we evaluated the effect of ivermectin (an antiparasitic drug) and herbicides on the body condition of 3 species of dung beetles collected in the field: Copris incertus, Euoniticellus intermedius, and Digitonthophagus gazella...Environ Toxicol Chem 2019;00:1-13.
  • ||||||||||  ivermectin oral / Generic mfg.
    New P2 trial:  ISSC: Ivermectin Safety in Small Children (clinicaltrials.gov) -  Apr 1, 2020   
    P2,  N=400, Not yet recruiting, 
  • ||||||||||  moxidectin / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis (clinicaltrials.gov) -  Feb 27, 2020   
    P3,  N=1000, Not yet recruiting, 
    Overall, the data suggest an al alarming condition created by multiple AR in Bangladesh. Trial completion date: Mar 2023 --> Oct 2023 | Initiation date: Nov 2019 --> Aug 2020 | Trial primary completion date: Mar 2023 --> Oct 2023
  • ||||||||||  albendazole / Generic mfg.
    Trial completion:  Twice Yearly Treatment for the Control of LF (clinicaltrials.gov) -  Feb 26, 2020   
    P4,  N=1462, Completed, 
    Trial completion date: Mar 2023 --> Oct 2023 | Initiation date: Nov 2019 --> Aug 2020 | Trial primary completion date: Mar 2023 --> Oct 2023 Recruiting --> Completed
  • ||||||||||  albendazole / Generic mfg.
    Enrollment status, Combination therapy:  DOLF IDA/Oncho: Safety and Efficacy of IDA for Onchocerciasis (clinicaltrials.gov) -  Jan 21, 2020   
    P2,  N=201, Enrolling by invitation, 
    Completed --> Enrolling by invitation | Trial completion date: Jul 2017 --> Jul 2020 Recruiting --> Enrolling by invitation
  • ||||||||||  albendazole / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  Efficacy and Safety of IVM/ALB Co-administration (clinicaltrials.gov) -  Sep 25, 2019   
    P2/3,  N=1960, Recruiting, 
    Recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting | Trial completion date: Aug 2019 --> Dec 2020 | Trial primary completion date: Aug 2019 --> Dec 2020
  • ||||||||||  ivermectin oral / Generic mfg.
    Enrollment open:  RIMDAMAL II: Repeat Ivermectin Mass Drug Administrations for MALaria Control II (clinicaltrials.gov) -  Aug 28, 2019   
    P3,  N=4700, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Aug 2019 --> Dec 2020 | Trial primary completion date: Aug 2019 --> Dec 2020 Not yet recruiting --> Recruiting
  • ||||||||||  ivermectin oral / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  Ocular Changes After Ivermectin - (DOLF IVM/Oncho) (clinicaltrials.gov) -  Apr 29, 2019   
    P=N/A,  N=231, Active, not recruiting, 
    Not yet recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting | Trial completion date: Jun 2019 --> Aug 2021 | Trial primary completion date: Mar 2019 --> Aug 2021
  • ||||||||||  ivermectin oral / Generic mfg.
    Enrollment change, Trial completion date, Trial initiation date, Trial withdrawal, Trial primary completion date:  Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis (clinicaltrials.gov) -  Apr 10, 2019   
    P2,  N=0, Withdrawn, 
    Enrolling by invitation --> Active, not recruiting | Trial completion date: Jun 2019 --> Aug 2021 | Trial primary completion date: Mar 2019 --> Aug 2021 N=12 --> 0 | Trial completion date: Mar 2019 --> Dec 2020 | Initiation date: Jul 2018 --> Dec 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jan 2019 --> Dec 2019
  • ||||||||||  ivermectin / Generic mfg., azithromycin / Generic mfg.
    Efficacy of mass co-administration to control scabies and impetigo in a highly endemic setting (HALL M) -  Apr 5, 2019 - Abstract #ECCMID2019ECCMID_4147;    
    N=12 --> 0 | Trial completion date: Mar 2019 --> Dec 2020 | Initiation date: Jul 2018 --> Dec 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jan 2019 --> Dec 2019 Ivermectin-based MDA can be scaled to a population of over 25,000 with a similar efficacy for scabies and impetigo as in smaller island populations and this level of efficacy can be achieved when MDA for scabies is integrated with azithromycin MDA for trachoma.
  • ||||||||||  ivermectin / Generic mfg.
    Ivermectin for adult patients with dengue infection (HALL M) -  Apr 5, 2019 - Abstract #ECCMID2019ECCMID_4035;    
    However, we did not demonstrate the clinical efficacy of ivermectin at this dosage regimen. Pharmacokinetic and pharmacodynamics study of ivermectin may help to understand this finding.
  • ||||||||||  ivermectin / Generic mfg.
    In vitro activity of ivermectin in combination with colistin against Gram-negative bacilli () -  Apr 5, 2019 - Abstract #ECCMID2019ECCMID_2539;    
    Ivermectin has potentiated the antibacterial effect of colistin against Col-S and Col-R A. baumannii, P. aeruginosa and K. pneumoniae. This effect might be due to the modification of OMPs being an attractive alternative for the treatment of GNB infections.
  • ||||||||||  ivermectin / Generic mfg., albendazole / Generic mfg.
    Review of Strongyloides stercoralis infections in Navarra in the last five years () -  Apr 5, 2019 - Abstract #ECCMID2019ECCMID_558;    
    Programs targeted at immigrants are needed to prevent and diagnose this infection. In the immunosuppressed it is important to make a screening before initiating an immunosuppressive therapy.
  • ||||||||||  azithromycin / Generic mfg.
    Trial completion, Trial primary completion date:  IVERAZITH: Treatment of Pediculosis (Head Lice) in Senegal (clinicaltrials.gov) -  Feb 27, 2019   
    P=N/A,  N=450, Completed, 
    Co-administration of MDA based on these two drugs opens up new potential for the control of neglected tropical diseases. Recruiting --> Completed | Trial primary completion date: Sep 2018 --> Jan 2019
  • ||||||||||  albendazole / Generic mfg.
    Trial initiation date:  Efficacy and Safety of IVM/ALB Co-administration (clinicaltrials.gov) -  Dec 4, 2018   
    P2/3,  N=1960, Not yet recruiting, 
    Recruiting --> Completed | Trial primary completion date: Sep 2018 --> Jan 2019 Initiation date: Sep 2018 --> Apr 2019